Acquirement
Lilly to Acquire Scorpion Therapeutics' Mutant-Selective PI3Kα Inhibitor Program
Eli Lilly and Company
PR-01-25-NI-14Jan 14, 2025
Breakthrough Results
Breakthrough Results for Jardiance® (Empagliflozin) Confirm Emperor-preserved as First and Only Successful Trial for Heart Failure with Preserved Ejection Fraction
Eli Lilly and Company
PR-M07-21-04Sep 05, 2024
M&A
Lilly Announces Acquisition of Protomer Technologies
Eli Lilly and Company
PR-M07-21-06Jul 15, 2021
Phase III
Lilly and Incyte's Baricitinib Improved Hair Regrowth for Alopecia Areata Patients in Second Phase 3 Study
Eli Lilly and Company
PR-M04-21-028-1017Apr 26, 2021
COVID-19
Lilly Modified COVID-19 Purchase Agreement for Bamlanivimab and Etesevimab Together
Eli Lilly and Company
PR-M04-21-010Apr 13, 2021
FDA Authorization
Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19
Eli Lilly and Company
PR-M11-20-022Nov 25, 2020
COVID-19
Lilly Announces Agreement with U.S. Government to Supply 300,000 Vials of Investigational Neutralizing Antibody to Fight COVID-19
Eli Lilly and Company
PR-M10-20-18-1207Oct 28, 2020
Lilly Statement on the NIAID Decision to Pause Enrollment in ACTIV-3 Clinical Trial
Eli Lilly and Company
PR-M10-20-09Oct 15, 2020
Oncology
Eli Lilly Drug Significantly Reduces the Risk of Breast Cancer Returning
Eli Lilly and Company
PR-M06-20-NI-020Jun 16, 2020
COVID-19 Clinical Testing
Lilly Begins Clinical Testing of Therapies for COVID-19
Nice Insight
PR-M04-20-NI-018Apr 13, 2020
New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.
Eli Lilly and Company
PR-M04-20-NI-010-1621Apr 07, 2020
Medical Professionals Across Merck, Pfizer, and Eli Lilly Volunteer Amid COVID-19 Pandemic
Eli Lilly and Company
PR-M04-20-NI-004 Apr 02, 2020
Coronavirus
Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines
Eli Lilly and Company
PR-M03-20-NI-020Mar 12, 2020
Partnership
Eli Lilly and Company to Partner in Support of the Olympic and Paralympic Games Tokyo 2020
Eli Lilly and Company
PR-M02-20-NI-030Feb 21, 2020
Investment
Governor Cooper Announces Over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant
Eli Lilly and Company
PR-M01-20-NI-034Jan 23, 2020
M&A
Lilly Announces Agreement to Acquire Dermira
Eli Lilly and Company
PR-M01-20-NI-032Jan 21, 2020
Drug Pricing
Lilly Expands Insulin Affordability Options
Eli Lilly and Company
PR-M01-20-NI-028Jan 17, 2020
Investment
Lilly Announces $400 Million Capital Investment in Manufacturing Facilities in Indianapolis
Eli Lilly and Company
PR-M11-19-NI-028Nov 20, 2019
Phase III
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib for Moderate to Severe Atopic Dermatitis
Eli Lilly and Company
PR-M09-19-NI-001Sep 03, 2019
Licensing Agreement
Innovent Enters a Licensing Agreement with Lilly to Develop & Commercialize a Novel Diabetes Medicine in China
Innovent
PR-M08-19-NI-076Aug 27, 2019